<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03733860</url>
  </required_header>
  <id_info>
    <org_study_id>AZ2017</org_study_id>
    <nct_id>NCT03733860</nct_id>
  </id_info>
  <brief_title>Cavernous Tissue Preservation During Penile Prosthesis Implantation</brief_title>
  <acronym>CTP</acronym>
  <official_title>Preservation of Penile Tumescence by Cavernous Tissue Preservation During Penile Prosthesis Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Spontaneous penile tumescence after penile prosthesis implantation has been previously
      reported as sporadically occurring during implant surgery. This study aims at systematically
      preserving residual erectile function, by the preservation of the patients' spontaneous
      penile tumescence by systematically sparing cavernous tissue during penile prosthesis
      implantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing the cavernous tissue sparing penile implant procedure will be injected
      intraoperatively with 40Âµg alprostadil, a prostaglandin E1 agonist intracorporal injection
      (ICI). The procedure will begin as soon as maximal tumescence is attained.

      In the cavernous sparing group, corporal dilation will be done solely with a size 8 dilator.
      The insertion of the dilator will be carefully inserted in what we call the path of least
      resistance. To determine the path of least resistance, the corporotomy is spread apart by
      pulling on previously set stay sutures. The path of least resistance is the plane with
      maximum outflow of blood from the intraoperatively pharmaceutically dilated and blood filled
      corpora cavernosa. This plane can also be anticipated with a preoperative penile duplex.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cavernous tissue thickness postoperatively measured by ultrasound</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence of spontaneous penile tumescence post operatively</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Cavernous sparing group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional technique group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cavernous tissue sparing penile prosthesis implantation</intervention_name>
    <description>Beginning penile prosthesis implantation (Coloplast Titan USA) procedure after intracavenosal injection of PGE1 prostine.</description>
    <arm_group_label>Cavernous sparing group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional penile prosthesis implantation</intervention_name>
    <description>Beginning penile implant procedure (Coloplast Titan USA) without prior intracavernosal injection of PGE1 prostine</description>
    <arm_group_label>Conventional technique group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intracavernosal injection of alprostadil</intervention_name>
    <description>Intraoperative intracavernosal injection of alprostadil in the cavernous sparing group</description>
    <arm_group_label>Cavernous sparing group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Erectile dysfunction not amenable to treatment by approved medical therapy

        Exclusion Criteria:

          -  Erectile dysfunction amenable to treatment by approved medical therapy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>81 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adham Zaazaa, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cairo University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 6, 2018</study_first_submitted>
  <study_first_submitted_qc>November 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2018</study_first_posted>
  <last_update_submitted>November 7, 2018</last_update_submitted>
  <last_update_submitted_qc>November 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Adham Zaazaa</investigator_full_name>
    <investigator_title>Assistant Lecturer</investigator_title>
  </responsible_party>
  <keyword>erectile dysfunction</keyword>
  <keyword>penile tumescence</keyword>
  <keyword>cavernous tissue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alprostadil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

